ECI® Approved by USDA as a Treatment for Bone Cancer in Dogs
ECI® is available at more than 100 authorized treatment centers across the United States
ECI® Approved by USDA as a Treatment for Bone Cancer in Dogs
ECI® is available at more than 100 authorized treatment centers across the United States
ELIAS Cancer Immunotherapy (ECI®) for Dogs
One in four dogs will develop cancer in their lifetime. Cancer is the leading cause of death in dogs over the age of two. It’s often discovered in late stages of the disease when treatment is difficult. Families of these pets are urgently looking for treatment options that not only prolong their companion’s life, but also improve quality of life.
ELIAS Animal Health, in collaboration with local veterinarians and veterinary hospitals, is helping these dogs and their families address this reality.
We Are Changing the Way Cancer is Fundamentally Treated
Cancer Immunotherapy. Personalized
The ELIAS Cancer Immunotherapy (ECI®) combines an autologous vaccine with cell therapy to target a patient’s unique cancer cells. This personalized approach can improve clinical outcomes and provide a better quality of life for canine patients.
Killer T cells. Activated.
The complexity of cancer itself makes the development and delivery of effective treatments a steep challenge. Research has shown that ex vivo activated T cells have the capability to effectively kill cancer cells. ECI® utilizes adoptive cell therapy to deliver an army of activated T cells.
Two Methods. Combined.
ELIAS Animal Health has developed a unique treatment protocol that vaccinates the dog with its own cancer cells to produce an immune response. Personalized T cells are then safely obtained from the patient through apheresis and activated to produce a large population of killer T cells that are reinfused into the patient to kill the cancer.
What Veterinarians Are Saying
Carolyn Henry, DVM, MS, DACVIM (Oncology)
Dean, College of Veterinary Medicine,
University of Missouri
Jeffrey Bryan, DVM, MS, PhD, DACVIM (Oncology)
Associate Professor & Director of the Comparative Oncology and Epigenetics Laboratory, College of Veterinary Medicine, University of Missouri